.svg){kind=small}
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab Therapeutics’ HMB-002 as a potential first-in-class subcutaneous therapy for von Willebrand disease (VWD). Richmond is now actively recruiting people with VWD for subsequent cohorts in Velora Pioneer.
Von Willebrand disease is the most common inherited bleeding disorder, with bleeding episodes that can range from frequent, low volume bleeds that impact daily living to potentially life-threatening events. Current treatment options for VWD primarily focus on reactively managing symptoms rather than addressing the underlying condition proactively.
HMB-002 is a monovalent antibody uniquely designed to increase levels of von Willebrand Factor (VWF) and Factor VIII. It is hoped that HMB-002 will provide a long-acting, subcutaneous prophylactic treatment for individuals with VWD, potentially transforming the standard of care for this condition.
Principal Investigator, Richmond’s Dr. Ulrike Lorch said: “Von Willebrand is a disease which affects over 12,000 people in the UK. We are delighted to be involved in a trial which may offer hope, not just for future generations of patients, but for those currently experiencing the day-to-day impacts of this often-debilitating condition.”
How to Participate in the Von Willebrand Trial
If you have VWD and are interested in participating in the trial, please visit Trials4Us where a representative from Richmond Pharmacology will contact you with more information.
More information about the Von Willebrand Disease trial can be found here.
Additional details about the Hemab Therapeutics clinical program for HMB-002 are available in the company’s official press release.
.avif)
